News from IMIM
The Food and Drug Administration's Center for Drug Evaluation and Research (FDA/CDER) and Chemotargets, a spin-off company from IMIM, will work together under a 5-year Research Collaboration Agreement (RCA).
The primary objective of the research agreement will be to assess the utility and performance of the Chemotargets CLARITY® intelligence & discovery platform to predict on-target and off-target activities using known pharmacology and safety data from experimental studies of small molecular entities.
Evaluating in silico models for broad pharmacological profiling is of interest to CDER to predict potential adverse events of drugs in development. Additionally, insight into a chemical’s molecular target profile can help predict abuse and addiction potential, which may reduce risks associated with exposure to these substances.